SANTIAGO
MORENO GUILLÉN
Investigador hasta 2007
Hospital Universitario Príncipe de Asturias
Alcalá de Henares, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Príncipe de Asturias (23)
2023
-
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125
-
Tuberculosis in Spain: An opinion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 6, pp. 562-583
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
2020
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202
2018
-
Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status
Cells, Vol. 7, Núm. 11
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
2015
-
Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus
Clinical Infectious Diseases, Vol. 60, Núm. 6, pp. 950-958
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792
2014
-
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis
Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 280-287
2011
-
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus
Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 12, pp. 2843-2849
2010
-
Opportunistic infections and organ-specific diseases in HIV-1-infected children: A cohort study (1990-2006)
HIV Medicine, Vol. 11, Núm. 4, pp. 245-252
2009
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092